Phase 2 N=81 Cardiovascular Effects of COVID-19
COVID-19
Primary: Hospital Length of Stay (LOS) — 5; 10; 25 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Efficacy, Safety and Local Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers
Healthy Subjects
Primary: Number of Participants Gaining Full Conjunctival Anesthesia of the Ocular Surface — 61; 2 Participants
Phase 2 N=378 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Uveal Melanoma
Primary: Efficacy: Overall Survival — 21.7; 16.0 Months — p=<0.0001
Phase 2 N=80 Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Systemic Lupus Erythematosus
Primary: Change in Vascular Function and Cardiometabolic Risk as Measured by Left CAVI at Month 3 — -0.32; 0.09 unitless
Phase 2 N=68 A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in Forced Vital Capacity (FVC) at Week 26 — 2865.43; 2817.08; -31.29; -79.47 mL — p=0.495
Phase 2 N=107 Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Myelofibrosis
Primary: Percentage of Participants With Spleen Response — 0; 10.2 percentage of participants
Phase 2 N=150 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Endometrial Atypical Hyperplasia · Endometrial Adenocarcinoma
Primary: Cumulative CR Rates Within 16 Weeks — 23; 12 Participants
Phase 2 N=177 Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
COVID-19
Primary: Percentage of Participants Alive and Free of Respiratory Failure at Day 14 — 83.1; 90.9 Percentage of participants
Phase 2 N=21 A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
Severe Postpartum Depression
Primary: Change From Baseline at End of Treatment Period (at 60 Hours) in Hamilton Rating Scale for Depression (HAM-D) Total Score — -8.75; -20.97 score on a scale — p=0.008
Phase 2 N=8 A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability — 4; 1; 1; 0 Participants
Phase 2 N=110 A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed — 8.7; 9.1; 19.0; 7.7 Percentage of…
Phase 2 N=23 Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Objective Response Rate — 0; 0 Participants
Phase 2 N=86 Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes
Type 1 Diabetes
Primary: Mean Glucose — 182; 165; 181; 165 mg/dl
Phase 2 N=18 Biomarkers of Irritant-Induced and Allergic Asthma
Asthma
Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change
Phase 2 N=62 Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
COVID-19
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 17; 15; 4; 6 Participants